Table 1.

Baseline characteristics

	Taxane (N = 175)	S-1 (N = 208)
Median age (range)	57.0 (33–75)	59.0 (29–75)
Hormone receptor status
ER positive, PgR positive, or both	127 (72.6)	149 (71.6)
ER negative and PgR negative	45 (25.7)	53 (25.5)
Unknown	3 (1.7)	6 (2.9)
HER2 status
Negative	162 (92.6)	192 (92.3)
Unknown	13 (7.4)	16 (7.7)
Components of (neo)adjuvant treatment
Oral fluoropyrimidine	26 (14.9)	22 (10.6)
Taxane	49 (28.0)	61 (29.3)
Endocrine therapy	100 (57.1)	111 (53.4)
Disease-free interval
≤2 years	34 (19.4)	41 (19.7)
2–5 years	52 (29.7)	66 (31.7)
≥5 years	58 (33.1)	67 (32.2)
No surgery	31 (17.7)	34 (16.3)
Liver metastasis
Yes	61 (34.9)	78 (37.5)
No	114 (65.1)	130 (62.5)